文献速递血栓与止血

静脉血栓栓塞与纤溶酶(原)无关:重新评估纤溶酶及降解纤维蛋白的机制

Venous thromboembolism is not associated with plasmin(ogen): reevaluating plasmin and mechanisms that degrade fibrin.
PubMed 文献 · Blood Adv · 2026-01-01

该综述基于临床与实验数据,挑战纤溶酶原激活与纤溶酶活性系统是预防静脉血栓栓塞所必需的经典观点。文章指出纤溶酶活性降低并不易感静脉血栓栓塞,并讨论代偿性血管与炎症通路等可能机制,提示静脉血栓栓塞是多因素疾病,纤溶系统受损既不必要也不充分驱动血栓形成。

要点

  • 纤溶酶活性降低不必然增加静脉血栓栓塞风险。
  • 静脉血栓栓塞是多因素疾病,纤溶受损非必要非充分。
  • 重新认识纤溶系统有助于平衡出血风险与血栓溶解的治疗策略。

核心结论

  • 静脉血栓栓塞与纤溶酶(原)系统受损不直接关联,纤溶系统受损既不必要也不充分驱动血栓形成。

研究设计与样本

  • 综述,基于临床与实验数据重新评估纤溶酶原激活与纤溶酶活性系统在静脉血栓栓塞中的作用。

主要发现

  • 临床与实验数据表明纤溶酶活性降低不 predispose 个体发生静脉血栓栓塞。
  • 代偿性血管和炎症通路可能降解血管内纤维蛋白,解释这一悖论。
  • 静脉血栓栓塞是多因素疾病,纤溶系统受损非必要非充分条件。

临床怎么用

  • 重新认识纤溶系统生物学有助于开发平衡出血风险与高效溶解血栓的疗法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The plasminogen activation and plasmin activity (PA) system is a central mechanism for degrading fibrin and has long been viewed as essential for preventing venous thrombosis/thromboembolism. However, clinical and experimental data challenge this paradigm. Here, we examine evidence that reduced PA does not predispose individuals to venous thrombosis/thromboembolism. We discuss potential mechanisms that may rationalize this apparent paradox, including compensatory vascular and inflammatory pathways that may degrade intravascular fibrin. These data suggest venous thromboembolism is a multifactorial disease in which an impaired PA system is neither necessary nor sufficient to drive thrombosis. We also discuss alternative biological roles of the PA system. Reframing the role of the PA system has important implications for developing therapies that modulate fibrinolysis. A more nuanced understanding of PA biology may enable strategies that balance bleeding risk with efficient clot resolution.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Sang Y, Shapiro AD, Wolberg AS, et al. Venous thromboembolism is not associated with plasmin(ogen): reevaluating plasmin and mechanisms that degrade fibrin. Blood Adv. 2026. PMID: 42476525. doi:10.1182/bloodadvances.2025018558

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。